Skip to main content
SpringerLink
Log in

Drug Treatment of Pneumococcal Pneumonia in the Elderly

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Streptococcus pneumoniae has been recognised as a major cause of pneumonia since the time of Sir William Osler. Drug-resistant S. pneumoniae (DRSP), which have gradually become resistant to penicillins as well as more recently developed macrolides and fluoroquinolones, have emerged as a consequence of indiscriminate use of antibacterials coupled with the ability of the pneumococcus to adapt to a changing antibacterial milieu. Pneumococci use cell wall choline components to bind platelet-activating factor receptors, colonise mucosal surfaces and evade innate immune defenses. Numerous virulence factors that include hyaluronidase, neuraminidase, iron-binding proteins, pneumolysin and autolysin then facilitate cytolysis of host cells and allow tissue invasion and bloodstream dissemination. Changes in pneumococcal cell wall penicillin-binding proteins account for resistance to penicillins, mutations in the ermB gene cause high-level macrolide resistance and mutations in topoisomerase IV genes coupled with GyrA gene mutations alter DNA gyrase and lead to high-level fluoroquinolone resistance.

Risk factors for lower respiratory tract infections in the elderly include age-associated changes in oral clearance, mucociliary clearance and immune function. Other risks for developing pneumonia include poor nutrition, hypoalbuminaemia, bedridden status, aspiration, recent viral infection, the presence of chronic organ dysfunction syndromes including parenchymal lung disease and recent antibacterial therapy. Although the incidence of infections caused by DRSP is rising, the effect of an increase in the prevalence of resistant pneumococci on mortality is not clear. When respiratory infections occur, rapid diagnosis and prompt, empirical administration of appropriate antibacterial therapy that ensures adequate coverage of DRSP is likely to increase the probability of a successful outcome when treating community-acquired pneumonia in elderly patients, particularly those with multiple risk factors for DRSP. A chest x-ray is recommended for all patients, but other testing such as obtaining a sputum Gram’s smear is not necessary and should not prolong the time gap between clinical suspicion of pneumonia and antibacterial administration.

The selection of antibacterials should be based upon local resistance patterns of suspected organisms and the bactericidal efficacy of the chosen drugs. If time-dependent agents are chosen and DRSP are possible pathogens, dosing should keep drug concentrations above the minimal inhibitory concentration that is effective for DRSP. Treatment guidelines and recent studies suggest that combination therapy with a β-lactam and macrolide may be associated with a better outcome in hospitalised patients, and overuse of fluoroquinolones as a single agent may promote quinolone resistance. The ketolides represent a new class of macrolide-like antibacterials that are highly effective in vitro against macrolide- and azalide-resistant pneumococci. Pneumococcal vaccination with the currently available polysaccharide vaccine is thought to confer some preventive benefit (preventing invasive pneumococcal disease), but more effective vaccines, such as nonconjugate protein vaccines, need to be developed that provide broad protection against pneumococcal infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV

Similar content being viewed by others

References

  1. Swartz MN. Attacking the pneumococcus: a hundred years’ war. N Eng J Med 2002; 346(10): 722

    Article  Google Scholar 

  2. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community acquired pneumonia. Clin Ther 1998; 20: 820–37

    Article  PubMed  CAS  Google Scholar 

  3. Niederman MS, Ahmed QAA. Community acquired pneumonia in elderly patients. Clin Geriatr Med 2003; 19: 101–20

    Article  PubMed  Google Scholar 

  4. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community acquired pneumonia: impact of age, co-morbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397–405

    PubMed  CAS  Google Scholar 

  5. Riquelme R, Torres A, El-Ebiary M, et al. Community acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450–5

    PubMed  CAS  Google Scholar 

  6. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730–54

    Google Scholar 

  7. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982; 96: 208–20

    PubMed  CAS  Google Scholar 

  8. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, singleblind population-based trial. Am J Med 1997; 103: 281–90

    Article  PubMed  CAS  Google Scholar 

  9. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol 2000; 40: 1057–67

    Google Scholar 

  10. Tuomanen E. Molecular and cellular biology of pneumococcal infection. Curr Opin Microbiol 1999; 2: 35–9

    Google Scholar 

  11. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 1998; 177: 368–77

    Article  PubMed  CAS  Google Scholar 

  12. Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Hemophilus influenza contributes to the persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998; 187: 631–40

    Article  PubMed  CAS  Google Scholar 

  13. Hakansson A, Kidd A, Wadell G, et al. Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae. Infect Immun 1994; 62: 2707–14

    PubMed  CAS  Google Scholar 

  14. Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J Leukoc Biol 2001; 69: 50–6

    PubMed  CAS  Google Scholar 

  15. Kostiukova NN, Volkova MA, Ivanova VV, et al. A study of pathogenic factors of Streoptococcus pneumoniae strains causing meningitis. FEMS Immunol Med Microbiol 1995; 10: 133–7

    Article  Google Scholar 

  16. Jedrzejas M. Pneumococcal virulence factors: structure and function. Microbiol Molec Biol Rev 2001; 65: 187–207

    Article  CAS  Google Scholar 

  17. Hammerschmidt S, Bethe G, Remane PH, et al. Identification of pneumococcal surface protein A as a lactoferrin binding protein of Streptococcus pneumoniae. Infect Immun 1999; 67: 1683–7

    PubMed  CAS  Google Scholar 

  18. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182: 1694–701

    Article  PubMed  CAS  Google Scholar 

  19. Bhakdi S, Tranum-Jensen J. Membrane damage by pore forming bacterial cytolysins. Microb Pathog 1986; 1: 5–14

    Article  PubMed  CAS  Google Scholar 

  20. Alcantara RB, Preheim LC, Gentry MJ, et al. Role of pneumolysin’s complement activating activity during pneumococcal bacteremia in cirrhotic rats. Infect Immun 1999; 67: 2862–6

    PubMed  CAS  Google Scholar 

  21. Braun JS, Novak R Gao G, et al. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun 1999; 67: 3750–6

    PubMed  CAS  Google Scholar 

  22. Tomasz A, Saukkonen K. The nature of cell wall derived inflammatory components of pneumococci. Pediatr Infect Dis J 1989; 8: 902–3

    Article  PubMed  CAS  Google Scholar 

  23. Tuomanen EI, Austrian R, Masure R. The pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 1280–4

    Article  PubMed  CAS  Google Scholar 

  24. Bergeron Y, Ouellet N, Deslauriers AM, et al. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66: 912–22

    PubMed  CAS  Google Scholar 

  25. Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001; 128: 28–31

    Article  Google Scholar 

  26. Meyer KC. Lung infections and aging. Aging Res Rev 2004; 3: 55–67

    Article  Google Scholar 

  27. Feldman C. Pneumonia in the elderly. Clin Chest Med 1999; 20: 563–73

    Article  PubMed  CAS  Google Scholar 

  28. Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994; 78: 1015–33

    PubMed  CAS  Google Scholar 

  29. Esposito AL. Pulmonary host defenses in the elderly. In: Niederman MS, editor. Respiratory infections in the elderly. New York: Raven Press, 1991: 25–44

    Google Scholar 

  30. Riquelme R, Torres A, El-Ebiary M,et al. Community acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997; 156: 1908–14

    PubMed  CAS  Google Scholar 

  31. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251–3

    PubMed  CAS  Google Scholar 

  32. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community acquired pneumonia. Arch Intern Med 1997; 157: 1453–9

    Article  PubMed  CAS  Google Scholar 

  33. Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged >75. Eur Respir J 2001; 17: 200–5

    Article  PubMed  CAS  Google Scholar 

  34. Starczewski AR, Allen SC, Vargas E, et al. Clinical prognostic indices of fatality in elderly patients admitted to the hospital with acute pneumonia. Age Aging 1988; 17: 181–6

    Article  CAS  Google Scholar 

  35. Wataakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. Arch Intern Med 1997; 157: 1965–71

    Article  Google Scholar 

  36. Ruiz-Gonzalez A, Falguera M, Nogues A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 16: 385–90

    Article  Google Scholar 

  37. Hansman D, Bullen MM. A resistant pneumococcus [letter]. Lancet 1967; II: 264–5

    Article  Google Scholar 

  38. Song JH, Lee NY, Ichiyama S, et al. Spread of drug resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 1999; 28: 1206–11

    Article  PubMed  CAS  Google Scholar 

  39. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: 764–70

    Article  PubMed  CAS  Google Scholar 

  40. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenza, and Moraxella cat-arrhalis in the United States: results from the TRUST surveillance program, 1999–2000. Clin Infect Dis 2002; 34 (1 Suppl.): 4S–16S

    Article  Google Scholar 

  41. Albanese BA, Roche JC, Pass M, et al. Geographic, demographic and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore. Clin Infect Dis 2002; 34: 15–21

    Article  PubMed  Google Scholar 

  42. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multi-drug resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338: 1861–8

    Article  PubMed  CAS  Google Scholar 

  43. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. National Committee for Clinical Laboratory Standards (NCCLS). Approved Standard NCCLS document M7-A5. Wayne (PA): NCCLS, 2001

  44. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160: 1399–408

    Article  PubMed  CAS  Google Scholar 

  45. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835–42

    PubMed  CAS  Google Scholar 

  46. Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with HIV seroprevalence. Clin Infect Dis 1999; 29: 321–7

    Article  PubMed  CAS  Google Scholar 

  47. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–9

    Article  PubMed  CAS  Google Scholar 

  48. Metlay JP, Hoffmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520–8

    Article  PubMed  CAS  Google Scholar 

  49. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003; 37: 230–7

    Article  PubMed  CAS  Google Scholar 

  50. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002; 34: 1613–20

    Article  PubMed  Google Scholar 

  51. Nagai K, Davies TA, Jacobs MR, et al. Effects of amino acid alterations in PBPs 1a, 2b, 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil and ceflacor in 18 clinical isolates of penicillin susceptible, intermediate and resistant pneumococci. Antimicrob Agents Chemother 2002; 46: 1273–80

    Article  PubMed  CAS  Google Scholar 

  52. Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae from a multicenter antibiotic resistance surveillance study conducted in the United States 1994–1995. Clin Infect Dis 1999; 29: 1186–8

    Article  PubMed  CAS  Google Scholar 

  53. Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 1999; 43: 1719–24

    PubMed  CAS  Google Scholar 

  54. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–64

    Article  PubMed  CAS  Google Scholar 

  55. Janoir C, Zeller V, Kitzis MD, et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40: 2760–4

    PubMed  CAS  Google Scholar 

  56. Sahm DF, Peterson DE, Critchley IA, et al. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000; 44: 2521–4

    Article  PubMed  CAS  Google Scholar 

  57. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–50

    Article  PubMed  Google Scholar 

  58. Anderson KB, Tan JS, File TM, et al. Emergence of levoflox-acin-resistant pneumococci in immunocompromised adults after therapy for community acquired pneumonia. Clin Infect Dis 2003; 37: 376–81

    Article  PubMed  Google Scholar 

  59. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-controlled study. Clin Infect Dis 2001; 32: 701–7

    Article  PubMed  CAS  Google Scholar 

  60. Hyde TB, Gay K, Stephan DS. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857–62

    Article  PubMed  CAS  Google Scholar 

  61. Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother 1999; 44: 1–6

    Article  PubMed  CAS  Google Scholar 

  62. Schito AM, Schito GC, Debbia E, et al. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999–2000. J Chemother 2003 Jun; 15(3): 226–34

    PubMed  CAS  Google Scholar 

  63. Clark JP, Langston E. Ketolides: a new class of antibacterial agents for the treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin Proc 2003; 78: 1113–24

    Article  PubMed  CAS  Google Scholar 

  64. Felmingham D. Microbiologic profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 2001; 7Suppl. 3: 2S–10S

    Google Scholar 

  65. Verhaejen J, Verbist L. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium. Acta Clin Belg 2001; 56: 349–53

    Google Scholar 

  66. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000; 45: 225–30

    Article  PubMed  CAS  Google Scholar 

  67. Ho PL, Ng TK, Yung RWH, et al. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant en-terococci in Hong Kong. J Antimicrob Chemother 2001 Oct 1; 48(4): 590–2

    Article  PubMed  CAS  Google Scholar 

  68. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475–80

    Article  PubMed  CAS  Google Scholar 

  69. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003 Nov; 124: 1789–97

    Article  PubMed  CAS  Google Scholar 

  70. Bryan CS, Talwani R, Stinson S, et al. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112: 1657–64

    Article  PubMed  CAS  Google Scholar 

  71. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agent Chemother 1999; 43: 672–7

    CAS  Google Scholar 

  72. White RL, Enzweiler KA, Friedrich LV, et al. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000. Diag Microbiol Infect Dis 2002; 43: 207–17

    Article  CAS  Google Scholar 

  73. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide antibiotic to a beta-lactam based empiric antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389–95

    Article  PubMed  CAS  Google Scholar 

  74. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in hospitalized patients with community acquired pneumonia. Arch Intern Med 1999; 159: 2576–80

    Article  PubMed  CAS  Google Scholar 

  75. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16: 308–18

    Article  PubMed  Google Scholar 

  76. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of the pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747–55

    Article  PubMed  CAS  Google Scholar 

  77. Mirzanejad Y, Roman S, Talot L, et al. Pneumococcal bacter-emia in two tertiary care hospitals in Winnipeg, Canada. Chest 1996; 109: 173–8

    Article  PubMed  CAS  Google Scholar 

  78. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged 65 and above: in the United States. MMWR Morb Mortal Wkly Rep 2002; 51(45): 1019–24

    Google Scholar 

  79. Ortqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J 2001; 18: 184–95

    Article  PubMed  CAS  Google Scholar 

  80. Powers DC, Anderson EL, Lottenbach K, et al. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173: 1014–8

    Article  PubMed  CAS  Google Scholar 

  81. Shelly MA, Jacoby H, Riley GJ, et al. Comparison of pneumo-coccal polysaccharide and CRM197-conjugated pneumococ-cal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 242–7

    PubMed  CAS  Google Scholar 

  82. Lottenbach KR, Mink CM, Barenkamp SJ, et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999; 67: 4935–8

    PubMed  CAS  Google Scholar 

  83. Briles DE, Tart RC, Swaitlo E, et al. PspA and PspC: their potential role for use as pneumococcal vaccines. Microb Drug Resist 1997; 3: 401–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This review was supported by University of Wisconsin Department of Medicine Funds. The authors have no conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Section of Pulmonary and Critical Care Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA

    Sridhar Neralla

  2. Lung Transplantation, Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA

    Keith C. Meyer

Authors
  1. Sridhar Neralla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith C. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith C. Meyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neralla, S., Meyer, K.C. Drug Treatment of Pneumococcal Pneumonia in the Elderly. Drugs Aging 21, 851–864 (2004). https://doi.org/10.2165/00002512-200421130-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421130-00003

Keywords

Search

Navigation